文献速递心力衰竭与心肌病冠心病

血管紧张素-(1-9)基因治疗可保护心肌梗死后左心室收缩功能

Gene Therapy With Angiotensin-(1-9) Preserves Left Ventricular Systolic Function After Myocardial Infarction.
PubMed 文献 · J Am Coll Cardiol · 2016-01-01

该研究在小鼠心肌梗死模型中通过尾静脉注射腺相关病毒载体递送血管紧张素-(1-9)基因,发现其可减少梗死后心脏性猝死,使收缩末期压力、射血分数、收缩末期容积及舒张末期压力-容积关系完全恢复,并通过蛋白激酶A依赖性机制直接增强心肌细胞钙瞬变幅度与收缩力。

要点

  • 小鼠心肌梗死后立即单次尾静脉注射AAV递送Ang-(1-9)基因可减少心脏性猝死。
  • Ang-(1-9)治疗使收缩末期压力、射血分数、收缩末期容积及舒张末期压力-容积关系完全恢复。
  • Ang-(1-9)通过蛋白激酶A依赖性机制直接增强分离心肌细胞钙瞬变幅度与收缩力。

核心结论

  • Ang-(1-9)基因治疗可保护心肌梗死后左心室收缩功能并恢复心脏功能,其直接通过蛋白激酶A依赖性机制影响心肌细胞钙处理,作者认为该基因治疗是心肌梗死背景下的一种潜在新策略。

研究设计与样本

  • C57BL/6小鼠行左前降支冠状动脉永久结扎,心肌梗死后立即经单次尾静脉注射腺相关病毒载体递送Ang-(1-9),用超声心动图评估心功能8周后终末测量左心室压力-容积环,并在分离的小鼠和人心肌细胞及离体Langendorff灌注全心模型中评估Ang-(1-9)对兴奋-收缩耦联和心脏收缩的直接效应。

主要发现

  • Ang-(1-9)基因递送减少了心肌梗死后心脏性猝死。
  • 压力-容积测量显示Ang-(1-9)治疗使收缩末期压力、射血分数、收缩末期容积及舒张末期压力-容积关系完全恢复。
  • Ang-(1-9)治疗组每搏输出量和心输出量较假手术组显著增加。
  • 组织学分析显示Ang-(1-9)对心脏肥厚和纤维化仅轻度影响,但显著增加瘢痕厚度。
  • 分离心肌细胞评估显示Ang-(1-9)通过增加钙瞬变幅度和收缩力产生正性肌力效应,Langendorff模型中Ang-(1-9)通过蛋白激酶A依赖性机制增加收缩。

临床怎么用

  • 原文未据此给出临床推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Angiotensin-(1-9) [Ang-(1-9)] is a novel peptide of the counter-regulatory axis of the renin-angiotensin-aldosterone system previously demonstrated to have therapeutic potential in hypertensive cardiomyopathy when administered via osmotic mini-pump. Here, we investigate whether gene transfer of Ang-(1-9) is cardioprotective in a murine model of myocardial infarction (MI). OBJECTIVES: The authors evaluated effects of Ang-(1-9) gene therapy on myocardial structural and functional remodeling post-infarction. METHODS: C57BL/6 mice underwent permanent left anterior descending coronary artery ligation and cardiac function was assessed using echocardiography for 8 weeks followed by a terminal measurement of left ventricular pressure volume loops. Ang-(1-9) was delivered by adeno-associated viral vector via single tail vein injection immediately following induction of MI. Direct effects of Ang-(1-9) on cardiomyocyte excitation/contraction coupling and cardiac contraction were evaluated in isolated mouse and human cardiomyocytes and in an ex vivo Langendorff-perfused whole-heart model. RESULTS: Gene delivery of Ang-(1-9) reduced sudden cardiac death post-MI. Pressure volume measurements revealed complete restoration of end-systolic pressure, ejection fraction, end-systolic volume, and the end-diastolic pressure volume relationship by Ang-(1-9) treatment. Stroke volume and cardiac output were significantly increased versus sham. Histological analysis revealed only mild effects on cardiac hypertrophy and fibrosis, but a significant increase in scar thickness. Direct assessment of Ang-(1-9) on isolated cardiomyocytes demonstrated a positive inotropic effect via increasing calcium transient amplitude and contractility. Ang-(1-9) increased contraction in the Langendorff model through a protein kinase A-dependent mechanism. CONCLUSIONS: Our novel findings showed that Ang-(1-9) gene therapy preserved left ventricular systolic function post-MI, restoring cardiac function. Furthermore, Ang-(1-9) directly affected cardiomyocyte calcium handling through a protein kinase A-dependent mechanism. These data emphasized Ang-(1-9) gene therapy as a potential new strategy in the context of MI.

来源:J Am Coll Cardiol,查看原文。版权归原作者所有。

引用

  1. Fattah C, Nather K, McCarroll CS, et al. Gene Therapy With Angiotensin-(1-9) Preserves Left Ventricular Systolic Function After Myocardial Infarction. J Am Coll Cardiol. 2016. PMID: 27978950. doi:10.1016/j.jacc.2016.09.946

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。